06.26.25 -- Outsourcing GLP-1 Programs: Is There Capacity For Biotechs?

With over 30+ years of experience, Catalent offers a comprehensive suite of orthogonal GMP analytical services for all biological modalities, from discovery to commercial phases. Our seasoned experts ensure exceptional on-time delivery and client satisfaction by providing tailored solutions to meet your unique needs—no matter the complexity, scale, or timeline. Watch our intro video to learn more about our capabilities!

Discover how strategically selecting and applying the right functional assessments can unlock the full potential of your therapeutic candidates and accelerate their path to success.

Observe two experimental methods for determining choked flow: the minimum controllable pressure method and the choke point method.

If you are wondering when to begin your CDMO search, the answer is simple: the sooner, the better. Partner with a CDMO early to help ensure later success.

Prior to reaching out to CDMOs for potential partnerships, think hard about exactly where you are as a sponsor in the outsourcing journey.

It is important to consider several factors in the overall development approach during the early phases in order to de-risk the late-phase development of your biologic drug product.

Delve into the key obstacles encountered in biologics process development, including the complexities of optimizing production processes, ensuring product consistency, and maintaining quality control.

Recognizing and integrating diversity, equity, and inclusion (DEI) is essential for fostering innovation, improving team performance, and ensuring long-term competitiveness in a global market.

Monoclonal antibody manufacturing is advancing to boost efficiency, cut costs, and expand access, driven by innovation, demand, and the rise of biosimilars.

Examine why optimizing drug formulations for solubility at physiological pH reduces injection site reactions, enables high-concentration dosing, and enhances patient comfort and compliance.

Utilize expert analytical testing services and unlock the potential of biosimilars, and bring cost-effective treatments to market faster.

Consider a standardized yet flexible modular biomanufacturing system designed to accelerate timelines, improve scalability, and enhance quality while reducing costs and environmental impact.

20-minute capacity and capabilities quick-looks, 20+ brand new CDMO presenters to evaluate for best-fit this quarter – and a (virtual) commitment of less than 20 percent of your day? We’re confident you don’t need 20/20 vision to see the value in this! Join us for Outsourced Pharma's July Partner Week – including sessions in Large Molecule Drug Substance, ADC, Analytical Services, and Fill/Finish among others. Registration, on-demand access, and interactive Q&A are free.

Director of Technical Transfer, JoAnne Jacobs, details the roots behind our team and our purpose: to deliver best-in-class CDMO services to help fulfill the increasing need for injectable drug product supply.

Explore how world-class contract manufacturing expertise and global capabilities can help accelerate your biologic from development to commercial success.

Understand the basic principles of analytical development for cGMP assays and the assays that are generally relevant to major biopharmaceutical modalities.

Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.

Whether you are ramping up for clinical trials or preparing for large-scale GMP production, review a variety of options tailored for a complete mAb process, available at both pilot and production scales.